Neupogen Singleject (Filgrastim)

Neupogen Singleject (filgrastim) is used to manage conditions involving impaired neutrophil production.

• Neutropenia associated with myelosuppressive chemotherapy: reduces the duration of severe neutropenia and lowers infection risk.
• Severe chronic neutropenia: increases absolute neutrophil count and improves clinical outcomes.
• Bone marrow transplantation: enhances neutrophil recovery after transplant.
• Peripheral blood progenitor cell mobilization: facilitates collection of CD34+ cells for autologous transplantation.

• Filgrastim binds to the specific cell‑surface receptor for granulocyte colony‑stimulating factor on hematopoietic progenitor cells. This interaction activates intracellular signaling pathways that promote proliferation, differentiation, and functional activation of neutrophil precursors, leading to an increased peripheral neutrophil count and improved innate immune response.

Filgrastim may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Bone pain: discomfort in the limbs or back.
• Injection site reactions: redness, swelling, or tenderness.
• Fever: low‑grade temperature elevation.
• Fatigue: feeling unusually tired.
• Headache: mild to moderate head discomfort.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Splenic rupture: sudden abdominal pain and shock.
• Acute respiratory distress syndrome: severe breathing difficulty.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Capillary leak syndrome: low blood pressure and edema.
• Leukocytosis: excessively high white‑blood‑cell count.
• Severe hypotension: sudden drop in blood pressure.

Before using Neupogen Singleject, clinicians should consider several safety measures.

• Monitor blood counts: regular CBC to assess neutrophil response.
• Assess splenomegaly: evaluate spleen size before and during therapy.
• Use caution in sickle‑cell disease: increased risk of vaso‑occlusive